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Abstract
The human ether-a `-go-go-1 (h-eag1) K
+ channel is expressed in a variety of cell lines derived from human malignant tumors
and in clinical samples of several different cancers, but is otherwise absent in normal tissues. It was found to be necessary
for cell cycle progression and tumorigenesis. Specific inhibition of h-eag1 expression leads to inhibition of tumor cell
proliferation. We report here that h-eag1 expression is controlled by the p532miR-342E2F1 pathway through a negative
feed-forward mechanism. We first established E2F1 as a transactivator of h-eag1 gene through characterizing its promoter
region. We then revealed that miR-34, a known transcriptional target of p53, is an important negative regulator of h-eag1
through dual mechanisms by directly repressing h-eag1 at the post-transcriptional level and indirectly silencing h-eag1 at
the transcriptional level via repressing E2F1. There is a strong inverse relationship between the expression levels of miR-34
and h-eag1 protein. H-eag1antisense antagonized the growth-stimulating effects and the upregulation of h-eag1 expression
in SHSY5Y cells, induced by knockdown of miR-34, E2F1 overexpression, or inhibition of p53 activity. Therefore, p53
negatively regulates h-eag1 expression by a negative feed-forward mechanism through the p532miR-342E2F1 pathway.
Inactivation of p53 activity, as is the case in many cancers, can thus cause oncogenic overexpression of h-eag1 by relieving
the negative feed-forward regulation. These findings not only help us understand the molecular mechanisms for oncogenic
overexpression of h-eag1 in tumorigenesis but also uncover the cell-cycle regulation through the p532miR-342E2F12h-
eag1 pathway. Moreover, these findings place h-eag1 in the p532miR-342E2F12h-eag1 pathway with h-eag as a terminal
effecter component and with miR-34 (and E2F1) as a linker between p53 and h-eag1. Our study therefore fills the gap
between p53 pathway and its cellular function mediated by h-eag1.
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Introduction
Abnormally enhanced proliferation often causes loss of control
of cell growth leading to tumorigenesis or cancer formation.
Several fundamental steps need to be fulfilled at the cellular level
for tumorigenesis and these steps can be roughly viewed as
characteristic alterations of some physicochemical processes: (1)
cell volume, (2) intracellular Ca
2+, and (3) intracellular pH.
Evidence has emerged indicating a deregulated expression of ion
channel protein-coding genes as well as ion channel malfunction as
an important step in the development and progression of cancers.
The ion channels critically related to cell proliferation and cancer
are the K
+ channels [1,2].
Of various categories of K
+ channels, the ether a ` go-go (eag)
voltage-dependent K
+ channel family stands out the most
attractive one in relation to tumor generation, progression and
metastasis [1–3]. Eag1 (or Kv10.1 encoded by KCNH1), the
founding member of the eag family, is restricted in its expression to
the nervous system, indicating that the channel is not normally
expressed in differentiated peripheral tissues. On the contrary, eag1
is expressed in a variety of cell lines derived from human
malignant tumors and in clinical samples of several different
cancers [1–17], while the surrounding tissues are devoid of eag1
expression. In these cell lines, eag1 enhances the proliferation of the
cells [13], and is required for the maintenance of growth. One of
the most intriguing aspects of human eag1 (h-eag1) channels is its
relationship to cellular transformation; h-eag1 channels are
necessary for progression through the G1 phase and G0/G1
transition of the cell cycle [13]. Cells transfected with h-eag1 are
able to grow in the absence of serum, lose contact inhibition, and
induce aggressive tumors when implanted into immune-depressed
mice [13]. Moreover, specific inhibition of eag1 expression by
antisense technique [13], siRNA [18] or antibody [19] leads to a
reduction in tumor cell proliferation in vitro and in vivo.
However, the molecular mechanisms underlying the oncogenic
overexpression of h-eag1 remained unexplored. Expression of
genes is tightly controlled by multiple factors at different levels.
Transcription factors generally bind to the respective cis-acting
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gene to switch on or off the transcription of the targeted gene [20].
In this way, transcription factors define the abundance of gene
expression at the transcriptional level. Recently, microRNAs
(miRNAs) have emerged as a new class of regulators of gene
expression [21]. These small non-protein-coding mRNAs primar-
ily elicit repression of protein translation by a partial complemen-
tary mechanism with its 59end 2–8 nts, the ‘‘seed site’’, base-paring
the sequence motif(s) in the 39 untranslated region (39UTR) of
target genes. In this way, miRNAs fine tune the expression of
genes at the post-transcriptional level. These facts imply that
transcription factors and miRNAs may somehow interplay and
coordinate to control the expression of genes and better
understanding of gene expression regulation should be addressed
at both layers. This study was designed to decipher the molecular
mechanisms underlying the oncogenic overexpression of h-eag1 by
identifying the genomic structure and the key transcription factor
that control the expression of h-eag1 at the transcriptional level and
by exploiting the potential role of miRNAs in fine-tuning the
expression of h-eag1 at the post-transcriptional level.
Results
In an initial effort to understand the molecular mechanisms for
oncogenic overexpression of eag1 in cancer cells, we characterized
the promoter region of the gene. We used 59RACE to identify the
transcription start site (TSS) which was found located to 152 bp
upstream the translation start codon (ATG) of h-eag1 (GenBank
accession No. DQ120124) (Figure S1). We then defined the
minimal promoter region by luciferase reporter gene assay
(Figure S2). Computer analysis revealed consensus sequences
for E2F1, AP2, and SP1 within the core promoter region (position
2630/+114), which might act as transactivators of h-eag1 gene.
Using the decoy oligodeoxynucleotide (dODN) approach
[20,22,23], which contains the perfect binding site for the target
transcription factor and can sequestrate the target leading to
reduction of transcriptional activity (Supporting Figures on-
line), we revealed a significant role of E2F1, but not of SP1 and
AP2, in driving the core promoter activity (Fig. 1A). Mutation of
the E2F1 cis-element rendered a loss of luciferase activity of the
core promoter. We further verified E2F1 as a key factor in
activating h-eag1 transcription: E2F1-dODN decreased h-eag1
mRNA level by ,80% in SHSY5Y human neuroblastoma cells
(Fig. 1B) and MCF-1 human breast cancer cells (Figure S3).
With qPCR, we have also ruled out the role of SP1 and AP2 in
transcriptional activation of h-eag1 (Fig. 1B). Transfection of E2F1
plasmid, on the other hand, increased h-eag1 mRNA level by as
much as 8-fold, which was diminished by E2F1-dODN. As a
negative control, transfection of SP1 plasmid did not significantly
alter h-eag1 mRNA level (Fig. 1C) despite that this maneuver was
able to enhance expression of h-erg1 at the mRNA level (Fig. 1C),
another member of the eag K
+ channel gene family, as already
established in our previous study [24]. The ability of E2F1 to bind
its cis-acting elements in the promoter region of h-eag1 was verified
using ChIP and EMSA (Fig. 1D & 1E). The transcription factor
E2F1 plays a pivotal role in the coordinated expression of genes
necessary for cell cycle progression and division, and is known to
be an oncoprotein critical for the transcriptional activation of
genes that control the rate of tumor cell proliferation [25–27]. Our
finding thus indicates a role of E2F1 in oncogenic upregulation of
h-eag1 expression at the transcriptional level.
We then investigated if h-eag1 is also regulated at the post-
transcriptional level by miRNAs. We first performed computa-
tional prediction of h-eag1 as a target for miRNA regulation. And
we identified multiple binding sites for a tumor-suppressor miRNA
subfamily miR-34 (including miR-34a, miR-34b and miR-34c) in the
39UTR of h-eag1 mRNA (Figure S4). To experimentally establish
miR-34:h-eag1 interaction, we inserted a fragment of 39UTR of h-
eag1 containing the miR-34 target sites into the position
downstream the luciferase gene in the pMIR-REPORTTM
vector. Transfection of miR-34a markedly suppressed the luciferase
activities and the effect was reversed by their multiple-target anti-
miRNA antisense oligonucleotides (MT-AMO) (Fig. 2A; Sup-
porting Figures online; Figure S5), a single oligomer capable
of targeting all three members of the miR-34 subfamily [28].
Consistently, miR-34a decreased the protein level of h-eag1 by
70% in SHSY5Y cells, as assessed by Western blot analysis,
whereas the MT-AMO increased it, presumably through down-
regulating the endogenous miR-34a/b/c (Fig. 2B). The h-eag1
antibody recognized two bands of 110 and 125 kDa, respectively,
which according to the study by Napp et al [29] represent core-
glycosylated form of eag1 protein and the complex N-Linked-
glycosylated form of eag1, respectively. We analyzed the
summation of the two bands to represent the total h-eag1 protein
level and both bands were found affected by miR-34 and MT-
AMO. The same observations were expanded to miR-34b and
miR-34c and to MCF-7 cells (Figure S6 & S7). Reduction of h-
eag1 expression was also seen at the mRNA level (Fig. 2C). Similar
results were observed in MCF-7 cells (Figure S7). As a negative
control, miR-1 did not produce any appreciable effects on h-eag1
expression.
It has been documented that miR-34a directly targets the
mRNA encoding E2F1 and significantly reduces the levels of E2F1
and E2F3 proteins [30–32]. We confirmed that transfection of
miR-34a reduced E2F1 protein levels by ,68% in SHSY5Y cells
(Fig. 3A) and the same results were obtained with miR-34b and
miR-34c (Figure S6 & S8). Moreover, application of the MT-
AMO caused significant increases in the protein levels of E2F1
(Fig. 3A) and h-eag1 (Fig. 2B). These results indicate that miR-34
regulates h-eag1 expression through at least two mechanisms. First,
miR-34 directly represses h-eag1 protein. Second, miR-34 represses
E2F1 protein, leading to reduced transcription of h-eag1. This
latter effect also explains partially the effectiveness of miR-34 to
decrease h-eag1 mRNA. This is supported by the experiments
showing the lack of effects of miR-34a on h-eag1 transcript level in
cells co-transfected with the E2F1-carrying vector that does not
contain the 39UTR of E2F1 gene (Fig. 3B). By comparison, miR-
34a retained its ability to repress h-eag1 protein in the presence of
E2F1 overexpression (Fig. 3C).
miR-34 has been known to be a direct transcriptional target of
p53 [33–36] and to mediate the apoptotic action of p53. Thus,
changes of p53 activity are deemed to change the level of miR-34
thereby those of E2F1 and h-eag1 as well. Indeed, p53 activation
by Mdm2 inhibitor nutlin-3 (1 mM) increased miR-34 level
(Fig. 4A), and simultaneously decreased E2F1 and h-eag1 mRNA
concentrations (Fig. 4A) and protein levels (Fig. 4B). These
changes were abrogated when the MT-AMO was co-applied with
Nutlin-3. Pifithrin-alpha (PFT-a;3 0 mM), the p53 inhibitor,
produced exactly the opposite effects to p53 activator. Evidently,
p53 negatively regulates expression of h-eag1. Moreover, in the
presence of p53 inhibitor, exogenously applied miR-34a retained
the full ability to downregulate E2F1 (Fig. 4C & 4D) and h-eag1
(Fig. 4E & 4F), suggesting that miR-34 mediates the regulatory
role of p53 on E2F1 and h-eag1. Furthermore, in the presence of
both p53 inhibitor and the MT-AMO, h-eag1 expression was
markedly upregulated at both mRNA and protein levels, but the
E2F1-dODN abolished these increases (Fig. 5A & 5B). On the
other hand, the downregulation of h-eag1 expression induced by
Regulation of EAG K
+ Channel by miR-34
PLoS ONE | www.plosone.org 2 May 2011 | Volume 6 | Issue 5 | e20362co-application of p53 activator and miR-34a was abolished by
E2F1 overexpression (Fig. 5C & 5D).
We reasoned that if E2F1 and miR-34 are indeed important in
the expression regulation of h-eag1, then we should see a positive
correlation between E2F1 and eag1 levels and an inverse
relationship between miR-34 and h-eag1 levels. Our data shown
in Figure S9 clearly demonstrate such relationships. It is noticed
that in non-cancer cell lines HEK293 (human embryonic kidney
cell), HMEC (human mammary epithelial cell) and HaVSMC
(human aortic vascular smooth muscle cell), E2F1 levels are low
and correspondingly, h-eag1 level is also low in these cells. In
particular, in comparison with HMEC, several breast cancer cell
lines (including 4T1 mouse mammary tumor cell line, and human
breast cancer cell lines BT-20, MCF-7 and SkBr-3) express high
levels of E2F1 and h-eag1 proteins.
These above data allowed us to propose a new signaling
pathway p532miR-342E2F12h-eag1 (Fig. 6). Thus, we next
sought to examine whether regulation of this pathway is related to
the cell growth profile. We first demonstrated that activation of
p53 by nutlin-3 induced a cell growth arrest in SHSY5Y cells, and
overexpression of E2F1 alleviated the cell growth inhibition and so
did transfection with the MT-AMO to knock down miR-34
(Fig. 7A & 7B). On the other hand, the direct growth-stimulating
effect of E2F1 was remarkably attenuated by inhibition of h-eag1
with the antisense oligodeoxynucleotides directed against h-eag1
gene but not by the sense oligomer for negative control (Fig. 7C &
7D). Further, inactivation of p53 by PFT-a or MT-AMO
promoted cell growth, which was abrogated by the antisense to
h-eag1 (Fig. 7E & 7F).
Discussion
The present study elucidated the molecular mechanisms under-
lying the oncogenic overexpression of h-eag1 at both transcriptional
and post-transcriptional levels. The major finding includes identifi-
cation of E2F1 as a key transcriptional activator of h-eag1 and miR-34
as an important translational inhibitor of h-eag1. In addition, we
confirmed the targeting of E2F1 by miR-34 and transactivation of
miR-34 by p53, and thus revealed the dual mechanisms by which
miR-34 controlsexpression of h-eag1: directly repressing h-eag1 at the
Figure 1. E2F1 as a transactivator of h-eag1 in SHSY5Y human neuroblastoma cells. (A) Role of E2F1 in driving the h-eag1 core promoter
activity. pGL3-Base: h-eag1 promoter-free pGL3 vector for control; pGL3-Core: pGL3 vector carrying the h-eag1 core promoter (a fragment spanning -
630/+114); E2F1-dODN, SP1-dODN, and AP2-dODN: the decoy oligodeoxynucleotides targeting E2F1, SP1, and AP2 transcription factors, respectively,
co-transfected with pGL3-Core; pGL3-Mutant: pGL3 vector carrying a mutated h-eag1 core promoter. Transfection was carried out using
lipofectamine 2000. *p,0.05 vs pGL3-Core; n=5 for each group. (B) Changes of h-eag1 mRNA level determined by real-time quantitative RT-PCR
(qPCR) in SHSY5Y cells. E2F1-dODN, E2F1-MT dODN, SP1-dODN, or AP2-dODN was transfected alone. Ctl/Lipo: cells mock-treated with lipofectamine
2000; E2F1-MT dODN: the decoy oligodeoxynucleotides targeting E2F1 with mutation at the core region. *p,0.05 vs Ctl/Lipo; n=5 for each group.
(C) Increase in h-eag1 mRNA level by overexpression of E2F1 in SHSY5Y cells transfected with the plasmid expressing the E2F1 gene. E2F1-P: pRcCMV-
E2F1 expression vector (Invitrogen), the plasmid carrying the E2F1 cDNA. *p,0.05 vs Ctl/Lipo; n=5 for each group. (D) Chromatin
immunoprecipitation assay (ChIP) assay for the presence of E2F1 on its cis-acting elements in the h-eag1 promoter region in SHSY5Y cells. Left
panel: the bands of PCR products of the 59-flanking region encompassing E2F1 binding sites following immunoprecipitation with the anti-E2F1
antibody or the anti-lamin A antibody for a negative control. Right panel: averaged data on the recovered DNA by anti-E2F1 expressed as fold
changes over anti-lamin A band. Input: the input representing genomic DNA prior to immunoprecipitation. (E) Electrophoresis mobility shift assay
(EMSA) for the fragment encompassing the putative E2F1 cis-acting element in the h-eag1 promoter region to bind E2F1 protein in the nuclear
extract from SHSY5Y cells. Probe: digoxigenin (DIG)-labeled oligonucleotides fragment containing E2F1 binding site; MT Probe: DIG-labeled fragment
containing mutated E2F1 site at the core motif; NE: nuclear extract from SHSY5Y cells. Solid arrowhead points to the shifted band representing the
DNA-protein complex. Note that the shifted band is weakened by anti-E2F1 antibody or with the mutant E2F1 binding motif.
doi:10.1371/journal.pone.0020362.g001
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transcriptional level through repressing E2F1. Finally, we demon-
strated that cell growth controls at the level of p53, miR-34 or E2F1
were related to h-eag1 expression.
Based on our findings, we were able to establish a novel
signaling pathway: p532miR-342E2F12 h-eag1. It appears that
h-eag1 is a terminal effecter component in the p532miR-
342E2F1 pathway for expression regulation and functional
signaling. When p53 activity increases in response to environ-
mental and cellular stresses, miR-34 is deemed to increase, and the
increased miR-34 will decrease E2F1 to diminish h-eag1 gene
transcription and will also repress h-eag1 protein translation as
well; diminishment of h-eag1 expression and function then results
in a shut-down of cell proliferation or a cell cycle arrest. This
implies that h-eag1 executes the cell-cycle checkpoint signal from
p53 transmitting along the p532miR-342E2F12h-eag1 pathway
(Fig. 6). Indeed, expression of h-eag1 is cell cycle-related; upon
synchronization of the cells in G1 phase with retinoic acid, eag1
current amplitude decreased to less than 5% of the control [13].
And retinoic acid has been showed to stimulate expression of miR-
34a accompanied by a decrease in E2F1 protein level [32]. These
findings may be extended to h-erg-1 K
+ channel (or HERG): h-
erg1 may also be a component of the p532miR-342E2F1
pathway, according to our data shown in Figures S3, S8 and S9.
The tumor-suppressor gene p53 and its downstream genes
consist of a complex molecular signaling network and p53 is at the
center of this network regulating diverse physiological responses to
cancer-related stresses. Activated p53 in response to DNA damage
or oncogene activation induces cell cycle arrest, which can be
transient or permanent (senescence), or promotes apoptosis in
cases where the damage is too severe; conversely, inactivation of
p53 causes oncogenic cell growth. Our study herein revealed that
miR-34, a known transcriptional target of p53, is an important
negative regulator of h-eag1 through dual mechanisms by direct
repression at the post-transcriptional level and indirect silencing at
the transcriptional level via post-transcriptionally repressing E2F1
that we have established to be a transactivator of h-eag1. p53
Figure 2. miR-34 as a post-transcriptional repressor of h-eag1.
(A) Repression of h-eag1 expression by miR-34a or miR-34c, as reported
by luciferase activity assay with the pMIR-REPORT
TM luciferase miRNA
expression reporter vector carrying the h-eag1 39UTR in HEK293 cells.
Ctl: cells transfected with the luciferase vector alone; MT-AMO: the
multiple-target anti-miRNA antisense oligonucleotides to miR-34a, miR-
34b and miR-34c, co-transfected with the luciferase vector and miR-34a
or miR-34c.* p,0.05 vs Ctl/Lipo;
wp,0.05 vs miR-34a; n=4 for each
group. (B) Western blot analysis revealing repression of h-eag1 protein
by miR-34a and miR-34c in SHSY5Y cells. *p,0.05 vs Ctl/Lipo;
wp,0.05
vs miR-34a alone; n=4 for each group. The immunoblot bands shown
were run on the same gel. (C) Effect of miR-34 on h-eag1 mRNA level in
SHSY5Y cells. *p,0.05 vs Ctl/Lipo;
wp,0.05 vs miR-34a alone; n=4 for
each group.
doi:10.1371/journal.pone.0020362.g002
Figure 3. miR-34 as a post-transcriptional repressor of E2F1. (A)
Effect of miR-34a on E2F1 protein levels in SHSY5Y cells. *p,0.05 vs Ctl/
Lipo;
wp,0.05 vs miR-34a alone; n=6 for each group. (B) Inability of
miR-34 to affect the overexpression of h-eag1 mRNA induced by
transfection of the plasmid expressing the E2F1 cDNA. *p,0.05 vs Ctl/
Lipo; n=4 for each group. (C) Repression of h=eag1 protein levels by
miR-34a in the presence of E1F1 overexpression by the vector
containing the E2F1 cDNA. *p,0.05 vs Ctl/Lipo;
wp,0.05 vs miR-34a
alone; n=4 for each group.
doi:10.1371/journal.pone.0020362.g003
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nutlin-3 (1 mM) on expression of miR-34, E2F1 and h-eag1 at mRNA and protein levels. SHSY5Y cells were pretreated with nutlin-3 and then
transfected with MT-AMO. *p,0.05 vs Ctl/Lipo;
wp,0.05 vs Nutlin-3 alone; n=4 for each group. (C & D) Downregulation of E2F1 at both mRNA and
protein levels by miR-34a in the presence of p53 inhibitor Pifithrin-alpha (PFT-a;3 0mM). SHSY5Y cells were pretreated with PFT and then transfected
with miR-34a. MT-AMO: an antisense oligomer to miR-34a, miR-34b and miR-34c; miR+AMO: co-transfection of miR-34a and MT-AMO; NC-miR:
scrambled negative control miRNA. Control cells were mock-treated with lipofectamine 2000. *p,0.05 vs Ctl/Lipo;
wp,0.05 vs miR-34a alone; n=4 for
each group. (E & F) Downregulation of h-eag1 at both mRNA and protein levels by miR-34a in the presence of p53 inhibitor Pifithrin-alpha (PFT-a;
30 mM). The immunoblot bands shown were run on the same gel. *p,0.05 vs Ctl/Lipo;
wp,0.05 vs miR-34a alone; n=4 for each group.
doi:10.1371/journal.pone.0020362.g004
Figure 5. Control of h-eag1 expression by E2F1. (A & B) Effect of E2F1 inhibition by its decoy oligodeoxynucleotides (E2F1-dODN) on h-eag1
expression at both mRNA and protein levels in the presence of both p53 inhibitor and the MT-AMO to miR-34. SHSY5Y cells were pretreated with PFT
(30 mM) and MT-AMO and then transfected with E2F1-dODN to sequestrate E2F1. *p,0.05 vs Ctl/Lipo;
wp,0.05 vs PFT+MT-AMO; n=4 for each group.
(C & D) Effect of E2F1 overexpression on h-eag1 expression in the presence of both p53 activator and miR-34a. SHSY5Y cells were pretreated with
nutlin-3 (1 mM) and miR-34a and then transfected with the plasmid to overexpress E2F1. *p,0.05 vs Ctl/Lipo;
wp,0.05 vs Nutlin-3+miR-34a; n=4 for
each group.
doi:10.1371/journal.pone.0020362.g005
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E2F1 and h-eag1; repression of E2F1 downregulates expression of
h-eag1. Therefore, p53 negatively regulates h-eag1 expression by a
negative feed-forward mechanism through the p532miR-
342E2F1 pathway and inactivation of p53 activity as it is the
case in many cancers can thus cause oncogenic overexpression of
h-eag1 by relieving the negative feed-forward regulation. These
findings not only help us understand the molecular mechanisms
for oncogenic overexpression of h-eag1 in tumorigenesis but also
uncover the cell-cycle regulation through the p532miR-
342E2F12h-eag1 pathway. Moreover, these findings place h-
eag1 in the p532miR-342E2F12h-eag1 pathway with h-eag as a
terminal effecter component and with miR-34 (and E2F1) as a
linker between p53 and h-eag1. Our study therefore fills a gap
between p53 pathway and its cellular function mediated by
h-eag1.
Intriguingly, it has been demonstrated that in vertebrates miR-
34 is initially expressed widespread throughout the brain in early
stage of development and expression becomes limited to the
anterior region of the hindbrain in later stages [37]. In adult, miR-
34 is absent from forebrain and midbrain and present only in the
caudal ventral and lateral isthmus and hindbrain nuclei [38]. This
low expression of miR-34 may partially underlie the high
abundance of eag1 in brain [39]. Moreover, this low level of
miR-34 may also explain the enriched expression of E2F1 in brain
[40]. Further, analysis of human specimens showed that miR-34a
expression is down-regulated in glioblastoma tissues as compared
with normal brain [41]. This can well result in upregulation of h-
eag1 during in tumorigenesis of brain. Indeed, downregulation of
miR-34 has been found in a wide spectrum of tumors [36] in one
hand and upregulation of h-eag1 in cancer tissues on the other
hand, consistent with h-eag1 being a CNS-localized voltage-gated
K
+ channel that is ectopically expressed in a majority of
extracranial solid tumors [39]. Recent studies have shown that
members of the miR-34 family possess anti-proliferative potential
and induce cell cycle arrest, senescence, and/or apoptosis [31–36].
Downregulation of miR-34 should produce the opposite changes
and upregulation of h-eag1 may mediate the cell growth-
promoting effect of miR-34 downregulation.
Materials and Methods
Rapid amplification of cDNA ends (59RACE)
The transcription start site (TSS) of h-eag1 gene was determined
with Ambion9s FisrtchoiceTM RNA–Ready cDNA Human Brain
Figure 6. Proposed model of the p532miR-342E2F12h-eag1
signaling pathway. RA: retinoic acid, which has been shown to
enhance miR-34 expression; E2F1/3: E2F1 and E2F3.
doi:10.1371/journal.pone.0020362.g006
Figure 7. Effects of the p532miR-342E2F12h-eag1 pathway on
cell proliferation. (A & B) Effects of p53 activation by nutlin-3 (1 mM),
E2F1 overexpression and miR-34 knockdown on SHSY5Y cell prolifer-
ation evaluated with MTT assay (A) and by population doubling time
(PDT) with flow cytometry methods (B). Cells were pretreated with
nutlin-3 to activate p53 and then transfected with the plasmid carrying
E2F1 cDNA for overexpression (E2F1-P) or MT-AMO to knockdown miR-
34; control cells (Ctl/Lipo) were mock-treated with lipofectamine 2000.
*p,0.05 vs Ctl/Lipo;
wp,0.05 vs Nutlin-3 alone; n=4 for each group. (C
& D) Effect of the antisense oligodeoxynucleotides (ASO) directed
against h-eag gene on SHSY5Y cell growth induced by E2F1
overexpression, evaluated with MTT assay (C) and by PDT using flow
cytometry methods (D). Cells were transfected with E2F1 plasmid alone
(E2F1-P) or co-transfected with E2F1 plasmid and ASO (+ASO) or SO
(sense oligomer for negative control; +SO). *p,0.05 vs Ctl/Lipo;
wp,0.05 vs E2F1-P alone; n=4 for each group. (E & F) Effects of
antisense to h-eag1 (ASO) on cell-growth stimulation by PTF-a-induced
p53 inactivation in SHSY5Y cells, determined by MTT (E) and by PDT (F).
Cells were pretreated with PFT-a (30 mM) to inactivate p53 or
transfected with MT-AMO, and then transfected with ASO; control cells
(Ctl/Lipo) were mock-treated with lipofectamine 2000. *p,0.05 vs Ctl/
Lipo;
wp,0.05 vs PFT-a alone; n=5 for each group.
doi:10.1371/journal.pone.0020362.g007
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42,43]. Human brain RNA sample was purchased from Clontech.
The gene specific primers (GSP) were designed based on the
human KCNH1 cDNA (GenBank accession HSU04270) for h-eag1;
GSP1 59-TTCACGGGCACCACATCCAC-39 (corresponding to
511–530 bp) and GSP2 (nest primer): 59-CCGAGCGTTGGC-
GATGATGA-39 (corresponding to 268–298 bp).
PCR amplification of putative promoter regions and
construction of promoter-luciferase fusion plasmids
A series of 39 to 59deletions were amplified with human genomic
DNA (Homo sapiens BAC clone RP11-543B16) as a template.
PCR products were subcloned into luciferase-containing pGL3-
Basic (Promega) vector [24,42,43]. Cis-acting elements for
transcription factor (TF) binding sites were analyzed with
MatInspector V2.2.
Decoy oligodeoxynucleotides for E2F1 (E2F1-dODN)
Single-stranded phosphorothioate oligodeoxynucleotides were
synthesized by Integrated DNA Technologies, Inc. (Coralville, IA).
The ODNs were washed in 70% ethanol, dried, and dissolved in
sterilized Tris-EDTA buffer (10 mM Tris and 1 mM EDTA). The
supernatant was purified using Micro Bio-Spin 30 columns (Bio-
Rad Laboratories, Hercules, CA) and quantified by spectropho-
tometry. The double-stranded E2F1-dODN was then prepared by
annealing complementary single-stranded oligodeoxynucleotides
by heating to 95uC for 10 min followed by cooling to room
temperature (RT) slowly over 2 h [20,24,42–44]. The E2F1-
dODN sequences are:
59-GCCCTCTTCGCGCCTCCCTCC-39
39-CGGGAGAAGCGCGGAGGGAGG-59; the mutated E2F1-
dODN sequences are:
59-GCCCTCTTCGatCCTCCCTCC-39
39-CGGGAGAAGCtaGGAGGGAGG-59 (the boldface and under-
lined letters indicate the core binding motif for E2F1 and the
mutated nucleotides are in lower case).
Antisense oligodeoxynucleotides to h-eag1 gene
Following the study reported by Pardo et al [14], a 19mer
antisense phosphorothioate oligodeoxynucleotides (ASO, 59-
CAGCCATGGTCATCCTCCC-39) spanning the putative initi-
ation codon of h-eag1 was used to test proliferation inhibition. The
sense oligodeoxynucleotides (SO, 59-GGGAGGATGACCATG-
GCTG-39) was used as a negative control.
Synthesis of miRNAs and anti-miRNA antisense inhibitors
miR-34a, miR-34b, and miR-34c (Figure S4), and their antisense
inhibitor oligonucleotides (MT-AMO) (Figure S5) were synthe-
sized by Integrated DNA Technologies, Inc. (IDT). The MT-
AMO tested in this study was designed to integrate the AMOs
against miR-34a, miR-34b and miR-34c into one AMO unit. An
eight-nucleotide linker was inserted to connect the two adjacent
antisense units and five nucleotides at both ends were locked with
methylene bridges (LNA), with the rest of residues at the form of
DNA.
Construction of chimeric miRNA target site2luciferase
reporter gene vectors
To construct reporter vectors bearing miRNA-target sites, the
39UTRs of h-eag1 and h-erg1 genes were inserted into the cloning
site downstream the luciferase gene in the pMIR-REPORTTM
luciferase miRNA expression reporter vector (Ambion, Inc)
[24,42–45].
Mutagenesis
Base-substitution mutations were made to the E2F1 binding site
in the promoter region the h-eag1 gene by PCR-based methods
[20]. The wild-type sequence is:
NNNNNTACCCTCGCGCCCTCTTCGCGCCTCCCTCCCTGCGGCCC-
GNNNNNN
NNNNNNATGGGAGCGCGGGAGAAGCGCGGAGGGAGGGACGCCGGG-
CNNNNNN, and the mutant sequence is (mutated nucleotides are shown
by the underlined lower-case letters):
NNNNNNTACCCTCGCGCCCTCgaCGatCCTCCCTCCCTGCGGCCC-
GNNNNNN
NNNNNNATGGGAGCGCGGGAGctGCtaGGAGGGAGGGACGCCGGG-
CNNNNNN. These sequences were cloned into the pGL3 vector for
luciferase activity assays.
Cell culture
The cell lines used in this study were all purchased from
American Type Culture Collection (ATCC, Manassas, VA).
SHSY5Y human dopaminergic neuroblastoma cells with wild-
type p53 status, MCF-7 human breast cancer cells with wild-type
p53 status and HEK293 human embryonic kidney cells were
cultured in Dulbecco’s Modified Eagle Medium (DMEM). The
cultures were supplemented with 10% fetal bovine serum and
100 mg/ml penicillin/streptomycin (Invitrogen).
Transfection and Luciferase Assay
For promoter activity measurements, HEK293 cells (1610
5/
well) were transfected with 1 mg pGL3–target DNA (firefly
luciferase vector) and 0.1 mg PRL-TK (TK-driven Renilla
luciferase expression vector), along with decoy ODNs or other
constructs, using lipofectamine 2000 (Invitrogen, Carlslbad, CA).
For miRNA experiments, HEK293 cells (1610
5/well) were
transfected with pMIR-REPORTTM vector along with miRNA
mimics, antisense ODNs, alone or together as to be specified. For
E2F1 overexpression, pRcCMV-E2F1 expression vector (Invitro-
gen) along with other constructs as specified was transfected. The
transfection procedures took place 24 h after starvation of cells in
serum-free medium. Following transfection (48 h), luciferase
activities were measured with a dual luciferase reporter assay kit
(Promega) on a luminometer (Lumat LB9507), as described
previously [42–47].
Western blot analysis
Following 48 h treatments, protein samples were extracted
by following the procedures essentially the same as described
in detail elsewhere [42–47]. The protein content was
determined with Bio-Rad Protein Assay Kit (Bio-Rad,
Mississauga, ON, Canada) using bovine serum albumin as
the standard. Protein sample (,30 mg) was fractionated by
SDS-PAGE (7.5%–10% polyacrylamide gels) and transferred
to PVDF membrane (Millipore, Bedford, MA). The sample
was incubated overnight at 4uC with the polyclonal anti-
rabbit primary antibodies for E2F1 (Santa Cruz) and h-eag1
(Alomone Labs), diluted 1:1000 in TBS containing 3% BSA.
Bound antibodies were detected using the chemiluminescent
substrate (Western Blot Chemiluminescence Reagent Plus,
NEN Life Science Products, Boston, USA). Western blot
bands were quantified using QuantityOne software by
measuring the band intensity (Area 6 OD) for each group
and normalizing to GAPDH (anti-GAPDH antibody from
Research Diagnostics Inc) as an internal control. The final
results are expressed as fold changes by normalizing the data
to the control values.
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For quantification of transcripts of E2F1 and h-eag1, conven-
tional real-time RT-PCR was carried out with total RNA samples
extracted from SHSY5Y human neuroblastoma cells 24 h after
treatments and treated with DNase I. TaqMan quantitative assay
of transcripts was performed with real-time two-step reverse
transcription PCR (GeneAmp 5700, PE Biosystems), involving an
initial reverse transcription with random primers and subsequent
PCR amplification of the targets. Expression level of GAPDH was
used as an internal control.
The mirVana
TM qRT-PCR miRNA Detection Kit (Ambion)
was used in conjunction with TaqMan real-time PCR for
quantification of miRNA transcripts in our study, following the
manufacturer’s instructions. The total RNA samples were isolated
with Ambion’s mirVana miRNA Isolation Kit. Reactions con-
tained mirVana qRT-PCR Primer Sets specific for human miR-
34a, miR-34b, miR-34c, miR-1 (as a negative control) and human 5S
rRNA (as a positive control). qRT-PCR was performed on a 96-
well StepOnePlusTM system (A&B Applied Biosystems) for 40
cycles. We first determined the appropriate cycle threshold (Ct)
using the automatic baseline determination feature. We then
performed dissociation analysis (melt-curve) on the reactions to
identify the characteristic peak associated with primer-dimers in
order to separate from the single prominent peak representing the
successful PCR amplification of miRNAs. Fold variations in
expression of miRNAs between RNA samples were calculated
[42-47].
Chromatin immunoprecipitation assay (ChIP)
ChIP assays were conducted with the EZ ChIP kit according to
the manufacturer’s instructions (Upstate Cell Signaling Solutions,
Lake Placid, NY) [24]. Briefly, SHSY5Y cells were grown to
subconfluency, washed and fixed in 1% formaldehyde for 10 min
to crosslink nucleoprotein complexes and scraped in phosphate
buffered saline containing protease inhibitor cocktail. Pelleted
cells were then lysed and sonicated in detergent lysis buffer.
Sheared DNA–protein complexes were immunoprecipitated by
incubating overnight the lysates with 2 mg antibodies against
E2F1 or lamin A (as a control). Protein A/G Plus beads (Santa
Cruz) were used, and after extensive washing, crosslinks were
removed at 65uC over overnight in an elution buffer (1% SDS,
0.1 M NaHCO3). The DNA was isolated using the QIAquick
PCR purification kit (Qiagen) and the presence of the h-eag1
promoter was analyzed by PCR amplification using 10% of
purified DNA. The primers used for h-eag1 promoter sequence
containing E2F1 cis-elements were 59GAGACCCTCACTCA-
GACGCA39 (forward) and 59CAGCACTAGGCTTCGGGTG-
G39 (reverse). The PCR products were analyzed by gel electrop-
horeses on an 8% non-denaturing polyacrylimide gel and
subsequent ethidium bromide staining.
Electrophoretic mobility shift assay (EMSA)
EMSA was performed with the DIG Gel Shift kit (Roche,
Mannheim, Germany). Varying amounts of nuclear protein
extracts from SHSY5Y cells were incubated with digoxigenin
(DIG)-labeled double-stranded oligonucleotides containing the
putative E2F1 cis-acting elements. For competition experiments,
100-fold excess of unlabeled double-stranded E2F1 consensus
oligonucleotides, and for super-shift experiments, 1 mg of E2F1
antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), were
added to the reaction. The generated chemiluminescent signals
were recorded on the X-ray film [20,24].
Drug treatment
For drug treatment, cells were starved in serum-free medium for
12 h and then incubated with the drugs at desired final
concentration for 1 h, followed by transfection of various
constructs. The drugs used included doxorubicin hydrochloride
(p53 activator, Biovision Research Products, Mountain View, CA)
and Pifithrin-alpha (PFT-a, p53 inhibitor; Cedarlane Lab Ltd,
Homby, ON). For experiments involving co-application of
activators and inhibitors, cells were pretreated with inhibitors for
5 h before addition of activators.
MTT assay for cell proliferation
The WST-1 kit (Roche, Penzberg, Germany). In brief, 24 h
after treatment with varying constructs, cells were washed with
PBS and grown in 100 ml of fresh culture medium plus 10 mlo f
WST-1 reagent for 30 min. The absorbance was measured at
425 nm using a Spectra Rainbow microplate reader (Tecan,
Gro ¨dig, Austria) with a reference wavelength of 690 nm
[20,47,48].
Determination of population doubling time (PDT)
Cell proliferation was assessed by characterizing the log phase
growth with population doubling time (PDT) calculated by using
the equation: 1/(3.32 6(logNH - logNI)/(t2 - t1), where NH is the
number of cells harvested at the end of the growth period (t2,2 4h )
and NI is the number of cells at 5 h (t1) after seeding [48].
Statistical analysis
Group data are expressed as mean 6 S.E. Statistical
comparisons (performed using ANOVA followed by Dunnett’s
method) were carried out using Microsoft Excel. A two-tailed
p,0.05 was taken to indicate a statistically significant difference.
Cis-elements for transcription factor binding sites were analyzed
with MatInspector V2.2.
Supporting Information
Figure S1 59-flanking region containing the core promoter
sequence of the h-eag1 (KCNH1) gene. The transcription start site
(TSS) is indicated by a backward arrow and designated position -1.
The TATA box and the consensus binding sequences for SP1,
AP2, and E2F transcription factors are underlined and the core
sequences of the cis-acting elements are bold. For convenience, the
E2F consensus sites are numbered in order from TSS and the
positions, relative to TSS, at the first nucleotide of the consensus
core sequence are donated by the numbers in the brackets.
(PDF)
Figure S2 Analysis of the h-eag1 promoter activity in various cell
lines. A schematic representation of the 59 deletion constructs of
the h-eag promoter region is shown on the left panel. Nucleotides
of fusion plasmids are numbered with respect to the TSS (-1)
identified by 59RACE. Firefly luciferase expression levels were
divided by co-expressed Renilla luciferase activity and expressed as
relative activity divided by the promoter-less construct (pGL3-
Basic). Shown is comparison of the h-eag1 promoter activities
expressed in three human cancer cell lines neuroblastoma
SHSY5Y, breast cancer MCF-7 and embryonic kidney cell
HEK293, and mouse atrial tumor cell line HL-1. The data were
averaged from 5 experiments in duplicate for each cell.
(PDF)
Figure S3 E2F1 as a transactivator of h-eag1 in MCF-7 human
breast cancer cell line. (A) Role of E2F1 in driving the h-eag1 core
promoter activity. pGL3-Base: h-eag1 promoter-free pGL3 vector
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PLoS ONE | www.plosone.org 8 May 2011 | Volume 6 | Issue 5 | e20362for control; pGL3-Core: pGL3 vector carrying the h-eag1 core
promoter (a fragment spanning -630/+114); E2F1-dODN, SP1-
dODN, and AP2-dODN: the decoy oligodeoxynucleotides
targeting E2F1, SP1, and AP2 transcription factors, respectively,
co-transfected with pGL3-Core; pGL3-Mutant: pGL3 vector
carrying a mutated h-eag1 core promoter. Transfection was
carried out using lipofectamine 2000. *p,0.05 vs pGL3-Core;
n=4 for each group. (B) Changes of h-eag1 mRNA level
determined by real-time quantitative RT-PCR (qPCR). E2F1-
dODN, E2F1-MT dODN, SP1-dODN, or AP2-dODN was
transfected alone. Ctl/Lipo: cells mock-treated with lipofectamine
2000; E2F1-MT dODN: the decoy oligodeoxynucleotides target-
ing E2F1 with mutation at the core region. *p,0.05 vs Ctl/Lipo;
n=4 for each group. (C) Increase in h-eag1 mRNA level by
overexpression of E2F1 in MCF-7 cells transfected with the
plasmid expressing the E2F1 gene. E2F1-P: pRcCMV-E2F1
expression vector (Invitrogen), the plasmid carrying the E2F1
cDNA. *p,0.05 vs Ctl/Lipo; n=4 for each group.
(PDF)
Figure S4 Multiple complementary motifs between each of the
three isoforms of has-miR-34 and the 39UTRs of h-eag1 mRNA (A)
and h-erg1 mRNA (B). Matched nucleotides are in boldface and
linked by ‘‘|’’, and wobble matches are indicated by ‘‘:’’.
(PDF)
Figure S5 The multiple-target anti-miRNA antisense oligonu-
cleotide fragment (MT-AMO) used to knock down all three
different isoforms of has-miR-34 (miR-34a, miR-34b and miR-34c).
(PDF)
Figure S6 Effects of miR-34b and miR-34c on expression of E2F1
(A) and h-eag1 (B) at the protein level in SHSY5Y cells, assessed
by Western blot analysis. Control cells were mock-treated with
lipofectamine 2000. miR-1 was used as a negative control. MT-
AMO: an antisense oligomer to miR-34a, miR-34b and miR-34c;
+MT-AMO: co-app;lication of miR-34c and MT-AMO. *p,0.05
vs Ctl/Lipo;
Qp,0.05 vs miR-34c alone; n=4 for each group.
(PDF)
Figure S7 miR-34 as a post-transcriptional repressor of h-eag1 in
MCF-7 human breast cancer cells. (A) Western blot analysis
revealing repression of h-eag1 protein by miR-34a.* p,0.05 vs Ctl/
Lipo;
Qp,0.05 vs miR-34a alone; n=5 for each group. (B) Effect of
miR-34a on h-eag1 mRNA level. *p,0.05 vs Ctl/Lipo;
Qp,0.05 vs
miR-34a alone; n=5 for each group.
(PDF)
Figure S8 Multiple complementary motifs between each of the
three isoforms of has-miR-34 and the 39UTR of E2F1 mRNA.
Matched nucleotides are in boldface and linked by ‘‘|’’, and
wobble matches are indicated by ‘‘:’’.
(PDF)
Figure S9 Expression correlations between E2F1 and h-eag1
and between miR-34 and h-eag1. (A) Western blot analysis showing
a positive correlation between E2F1 protein and h-eag1 protein
levels in various cancer and non-cancer cell lines as specified. Fill
circles are experimental data, straight line represents linear
regression and dashed lines define the 95% confidence range.
The correlation coefficient (r
2) and the slope are indicated. (B)
qPCR analysis showing an inverse relationship between miR-34a/b
and h-eag1 protein levels in HMEB, HaVSMC, SkBr-3, SHSY5Y,
U2OS, HT29, and Sk-28 cells. Fill circles are experimental data,
straight line represents linear regression and dashed lines define
the 95% confidence range. The correlation coefficient (r
2) and the
slope are indicated.
(PDF)
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